Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2

Recent advances in targeting leukemic stem cells (LSCs) using venetoclax with azacitidine (ven + aza) has significantly improved outcomes for de novo acute myeloid leukemia (AML) patients. However, patients who relapse after traditional chemotherapy are often venetoclax-resistant and exhibit poor clinical outcomes. We previously described that fatty acid metabolism drives oxidative phosphorylation (OXPHOS) and acts as a mechanism of LSC survival in relapsed/refractory AML. Here, we report that chemotherapy-relapsed primary AML displays aberrant fatty acid and lipid metabolism, as well as increased fatty acid desaturation through the activity of fatty acid desaturases 1 and 2, and that fatty acid desaturases function as a mechanism of recycling NAD+ to drive relapsed LSC survival. When combined with ven + aza, the genetic and pharmacologic inhibition of fatty acid desaturation results in decreased primary AML viability in relapsed AML. This study includes the largest lipidomic profile of LSC-enriched primary AML patient cells to date and indicates that inhibition of fatty acid desaturation is a promising therapeutic target for relapsed AML.

[1]  D. Chan,et al.  SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells , 2021, Theranostics.

[2]  Gary D Bader,et al.  Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. , 2021, Cell stem cell.

[3]  Tariq A. Akhtar,et al.  Very long chain fatty acid metabolism is required in acute myeloid leukemia. , 2021, Blood.

[4]  C. Jordan,et al.  Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting , 2020, STAR protocols.

[5]  Austin E. Gillen,et al.  Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells , 2020, Nature Cancer.

[6]  Gary D Bader,et al.  Nicotinamide Phosphoribosyltransferase Inhibitors Selectively Induce Apoptosis of AML Stem Cells by Disrupting Lipid Homeostasis , 2020 .

[7]  A. D’Alessandro,et al.  Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. , 2020, Cell stem cell.

[8]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[9]  Anping Li,et al.  The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017 , 2020, Journal of Hematology & Oncology.

[10]  F. Arfuso,et al.  Aberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells , 2019, Stem cells.

[11]  A. Schimmer,et al.  Phospholipid metabolism regulates AML growth and stemness , 2019, Aging.

[12]  J. Florez,et al.  Polyunsaturated Fatty Acid Desaturation Is a Mechanism for Glycolytic NAD+ Recycling. , 2019, Cell metabolism.

[13]  B. Faubert,et al.  Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity , 2019, Nature.

[14]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[15]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[16]  M. Goodell,et al.  Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9 , 2018, Journal of visualized experiments : JoVE.

[17]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[18]  D. Pollyea,et al.  Therapeutic targeting of acute myeloid leukemia stem cells. , 2017, Blood.

[19]  J. Idle,et al.  The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features , 2017, BBA clinical.

[20]  E. Lengyel,et al.  Unsaturated Fatty Acids Maintain Cancer Cell Stemness. , 2017, Cell stem cell.

[21]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[22]  P. Crooks,et al.  Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. , 2015, Journal of medicinal chemistry.

[23]  A. D’Alessandro,et al.  Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry , 2015, Amino Acids.

[24]  John M. Ashton,et al.  Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. , 2013, Blood.

[25]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[26]  J. Rowe,et al.  The myth of the second remission of acute leukemia in the adult. , 2013, Blood.

[27]  J. Dick,et al.  A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. , 2012, Blood.

[28]  G. Giaever,et al.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.

[29]  J. Heinrich,et al.  Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism. , 2010, Metabolism: clinical and experimental.

[30]  H. Kantarjian,et al.  Late relapses in acute myeloid leukemia: analysis of characteristics and outcome , 2010, Leukemia & lymphoma.

[31]  Zhongming Ma,et al.  The increase of cell-membranous phosphatidylcholines containing polyunsaturated fatty acid residues induces phosphorylation of p53 through activation of ATR , 2007, Journal of Cell Science.

[32]  P. Moreau.  Lipids , 2007 .

[33]  M. Crawford,et al.  Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat , 1987, British Journal of Nutrition.

[34]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[35]  J. C. Arroyave,et al.  Molecular biomarkers in acute myeloid leukemia. , 2017, Blood reviews.